Abstract

The emergence of fungal “superbugs” resistant to the limited cohort of anti-fungal agents available to clinicians is eroding our ability to effectively treat infections by these virulent pathogens. As the threat of fungal infection is escalating worldwide, this dwindling response capacity is fueling concerns of impending global health emergencies. These developments underscore the urgent need for new classes of anti-fungal drugs and, therefore, the identification of new targets. Phosphoinositide signaling does not immediately appear to offer attractive targets due to its evolutionary conservation across the Eukaryota. However, recent evidence argues otherwise. Herein, we discuss the evidence identifying Sec14-like phosphatidylinositol transfer proteins (PITPs) as unexplored portals through which phosphoinositide signaling in virulent fungi can be chemically disrupted with exquisite selectivity. Recent identification of lead compounds that target fungal Sec14 proteins, derived from several distinct chemical scaffolds, reveals exciting inroads into the rational design of next generation Sec14 inhibitors. Development of appropriately refined next generation Sec14-directed inhibitors promises to expand the chemical weaponry available for deployment in the shifting field of engagement between fungal pathogens and their human hosts.

Highlights

  • The human population carries a remarkable load of commensal microorganisms that execute functions beneficial to the human host

  • We focus on future prospects for expanding the dwindling antifungal drug arsenal with primary emphasis on targeting phosphoinositide signaling, phosphatidylinositol transfer proteins (PITPs)-dependent phosphatidylinositol 4-phosphate [PtdIns(4)P] signaling in these pathogens

  • There are no Sec14-like proteins/domains expressed by mammals that carry a PtdCho-binding barcode—suggesting no mammalian Sec14-like protein will be inadvertently targeted by NPPM- or picolinamide-based inhibitors of fungal Sec14 PITPs

Read more

Summary

Introduction

The human population carries a remarkable load of commensal microorganisms that execute functions beneficial to the human host. While superficial fungal infections in humans are commonplace, overgrowth of commensal fungi can develop into life-threatening systemic infections Such deep fungal invasions represent an escalating health problem worldwide and claim in excess of 1.5 million lives annually [3,4]. These diseases come with mortality rates surpassing those associated with many viral and bacterial infections [5]. We briefly discuss the current status of antifungal drug therapy and the urgent need for development of new tools for chemical intervention This urgency is fueled by the rapidly climbing incidence of human fungal diseases, coupled with the rise of multi-drug-resistant fungal pathogens. While the discussion focuses on Candida as infectious agent, these concepts translate to other fungal pathogens as well

Virulence of Candida Species
Therapeutic Options for Treating Candidiasis
Multidrug-Resistant Fungal Pathogens
New Targets and Next Generation Anti-Fungal Compounds
Phosphoinositide Signaling
Mechanisms of PITP Function
10. Sec14 Orthologs in Virulent Fungi
12. Mechanisms of Sec14 Inhibition and the PtdCho Headgroup Binding Site
13. The Sec14 VV-Motif Drug Sensitivity Signature
15. Pharmacophore and Future Design Considerations
16. A Sec14-Directed Natural Product with Potent Anti-Fungal Activity?
17. Sec14-Directed Anti-Fungals and Prospective Mechanisms of Drug Resistance
18. Conclusions
Findings
66. CDC Website
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call